ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Overview
USA - NASDAQ:ALNY - US02043Q1076 - Common Stock
ALNY Key Statistics, Chart & Performance
The current stock price of ALNY is 449.56 USD. In the past month the price decreased by -2.48%. In the past year, price increased by 64.13%.
ALNY Latest News, Press Relases and Analysis
ALNY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ARGX | ARGENX SE - ADR | 89.07 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.96 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 9.34 | 21.93B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.19 | 20.51B |
Related stock screener links
About ALNY
Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Company Info
ALNYLAM PHARMACEUTICALS INC
675 W Kendall St
Cambridge MASSACHUSETTS 02142 US
CEO: John M. Maraganore
Employees: 2230
Phone: 16175518200
ALNYLAM PHARMACEUTICALS INC / ALNY FAQ
Can you describe the business of ALNYLAM PHARMACEUTICALS INC?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
What is the stock price of ALNYLAM PHARMACEUTICALS INC today?
The current stock price of ALNY is 449.56 USD. The price decreased by -6.65% in the last trading session.
Does ALNYLAM PHARMACEUTICALS INC pay dividends?
ALNY does not pay a dividend.
What is the ChartMill rating of ALNYLAM PHARMACEUTICALS INC stock?
ALNY has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ALNYLAM PHARMACEUTICALS INC (ALNY) based on its PE ratio?
ALNYLAM PHARMACEUTICALS INC (ALNY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.47).
Can you provide the growth outlook for ALNYLAM PHARMACEUTICALS INC?
The Revenue of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 57.74% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for ALNYLAM PHARMACEUTICALS INC?
ALNYLAM PHARMACEUTICALS INC (ALNY) has a market capitalization of 58.93B USD. This makes ALNY a Large Cap stock.
ALNY Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ALNY. When comparing the yearly performance of all stocks, ALNY is one of the better performing stocks in the market, outperforming 88.57% of all stocks.
ALNY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALNY. The financial health of ALNY is average, but there are quite some concerns on its profitability.
ALNY Financial Highlights
Over the last trailing twelve months ALNY reported a non-GAAP Earnings per Share(EPS) of -2.47. The EPS decreased by -311.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.99% | ||
| ROE | -127.33% | ||
| Debt/Equity | 4.1 |
ALNY Forecast & Estimates
36 analysts have analysed ALNY and the average price target is 458.7 USD. This implies a price increase of 2.03% is expected in the next year compared to the current price of 449.56.
For the next year, analysts expect an EPS growth of 164.21% and a revenue growth 57.74% for ALNY